Developing the next generation of nanomedicines.
Development of therapies based on the unique functions of miRNAs with a focus on oncology.
Tackling “undruggable” targets with small molecule inhibitors of intracellular protein-protein interactions.
A new therapeutic approach in immune-oncology, targeting the tumor microenvironment.
A leading Organ-on-a-Chip Company developing human tissue and disease models for tomorrow’s medicines, chemicals and food.
Switching from intravenous-to-oral cancer treatment.
Oncolytic adenovirus technologies.
Enabling endosomal escape of macromolecule therapeutics.
Fully synthetic therapeutic vaccines against cancer and persistent viral infections.
Bispecific antibodies which are targeting solid tumors and blood tumors.
Antibody Drug Conjugate Technologies.
Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting